A Vertex drug hit its mark in a Phase 2 study in chronic pain, but faces questions about its performance versus placebo.
Vertex's closely watched drug, suzetrigine, reduced sciatica pain compared to baseline but did not outperform a placebo ...
Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...
The scale lists the numbers one through ten with the number one representing the absence of pain and the number ten representing the worst pain imaginable. The nurse should explain the scale to ...
Investor's Business Daily on MSN23h
Vertex Dives 11% On A 'Worst-Case Scenario' For Its Non-Opioid Pain DrugVertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower ...
A new, presumably more precise or, hopefully, more relevant, pain scale, named the Detroit Interventional Pain Management ...
US biopharma Vertex Pharmaceuticals today announced results from its Phase II study of suzetrigine, an investigational, oral, ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from its Phase 2 study of suzetrigine, an ...
Many women who have taken abortion pills say they were unprepared for how much the procedure would hurt, a study has found.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback